Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, a full-spectrum cannabis extract (VER-01) was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to approximately one year. The trial design is rigorous, including a randomized withdrawal phase to assess durability of effect. Results from this study will help clarify whether full-spectrum cannabis preparations offer a clinically meaningful and safe alternative to conventional analgesics for one of the most prevalent pain conditions globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant safety concerns. The large sample size (820 participants), double-blind design, and extended follow-up period strengthen the evidentiary foundation for evaluating VER-01 as a potential alternative to conventional analgesics and their associated risks. If efficacious and well-tolerated, this full-spectrum extract could expand the therapeutic armamentarium for CLBP management and inform evidence-based clinical decision-making regarding cannabinoid pharmacotherapy.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of full-spectrum Cannabis sativa extract for chronic low back pain represents meaningful progress in addressing a substantial unmet clinical need, given the limitations and risks of conventional analgesics. The enrollment of 820 participants with a 12-week double-blind phase followed by extended open-label observation provides a reasonably robust framework, though the efficacy signal and safety profile remain crucial details absent from this abstract. Key considerations for clinical interpretation include the heterogeneity of full-spectrum extracts across batches, the specific cannabinoid and terpene composition of VER-01, potential bias in the open-label extension phase, and how outcomes compare to existing multimodal approaches for CLBP. Providers should await the full publication to assess effect size magnitude, number needed to treat, adverse event rates, and any subgroup analyses that might identify patients most likely to benefit. If efficacy is demonstrated with an acceptable safety profile, this could offer a non-opioid option for carefully selected CLB